Insmed (NASDAQ:INSM) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Representative Gilbert Ray Cisneros, Jr. sold between $1,001 and $15,000 of Insmed stock on September 22, 2025, as disclosed in a filing on October 10th.
• Insmed's quarterly earnings report showed a loss of ($1.70) per share, falling short of the expected ($1.30), despite an 18.9% increase in revenue year-over-year.
• Insider selling at Insmed has been significant, with insiders unloading over $27 million in shares in the last ninety days, highlighting a potential shift in confidence among company executives.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. NASDAQ: INSM. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on September 22nd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 10/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 10/1/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 9/30/2025.
• Sold $15,001 - $50,000 in shares of Fortive NYSE: FTV on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 9/30/2025.
• Sold $1,001 - $15,000 in shares of GoDaddy NYSE: GDDY on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 9/30/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi Heavy Industries OTCMKTS: MHVYF on 9/30/2025.

Insmed Stock Performance

Insmed stock traded down $1.33 during midday trading on Tuesday, hitting $162.61. The company's stock had a trading volume of 515,331 shares, compared to its average volume of 2,692,869. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $166.44. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company has a 50-day moving average price of $139.14 and a two-hundred day moving average price of $102.76. The company has a market cap of $34.37 billion, a price-to-earnings ratio of -28.42 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter last year, the firm earned ($1.94) EPS. Insmed's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider owned 36,461 shares in the company, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares in the company, valued at approximately $7,546,758.35. The trade was a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 211,057 shares of company stock worth $27,438,126 over the last ninety days. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of INSM. Wealth Enhancement Advisory Services LLC lifted its position in shares of Insmed by 10.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company's stock valued at $223,000 after acquiring an additional 307 shares during the period. NBC Securities Inc. acquired a new position in shares of Insmed during the 1st quarter valued at $49,000. Park Avenue Securities LLC lifted its position in shares of Insmed by 38.7% during the 1st quarter. Park Avenue Securities LLC now owns 11,036 shares of the biopharmaceutical company's stock valued at $842,000 after acquiring an additional 3,081 shares during the period. GAMMA Investing LLC lifted its position in shares of Insmed by 62.0% during the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 386 shares during the period. Finally, Handelsbanken Fonder AB lifted its position in shares of Insmed by 8.6% during the 1st quarter. Handelsbanken Fonder AB now owns 49,181 shares of the biopharmaceutical company's stock valued at $3,752,000 after acquiring an additional 3,900 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on INSM. William Blair assumed coverage on shares of Insmed in a research report on Wednesday, August 20th. They issued an "outperform" rating for the company. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a report on Wednesday, August 20th. UBS Group boosted their target price on shares of Insmed from $140.00 to $194.00 and gave the stock a "buy" rating in a report on Tuesday. Evercore ISI reissued an "outperform" rating and set a $180.00 target price on shares of Insmed in a report on Wednesday, October 1st. Finally, Mizuho boosted their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $152.88.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.